Last update Sept. 23, 2023

C6468H10016N1728O2012S47

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Lanadelumab is a human monoclonal antibody that inhibits plasma kallikrein, limiting the production of bradykinin, a potent vasodilator. It is used to treat and prevent attacks of hereditary angioedema. It is administered by subcutaneous injection every 2 weeks.

As of the last update, we found no published data on its excretion in breast milk.

Its very high molecular weight makes it unlikely to be excreted in breast milk.

Due to its protein nature, it is inactivated in the gastrointestinal tract and is not absorbed (oral bioavailability practically nil), which makes it difficult or impossible for it to pass into infant plasma from ingested breast milk, except in premature infants and in the immediate neonatal period, in which there may be greater intestinal permeability.

Pending further published data on this drug in relation to lactation, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity. (Yeich 2023, Bouillet 2015)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

C6468H10016N1728O2012S47 is Lanadelumab in Molecular formula.

Is written in other languages:

Groups

C6468H10016N1728O2012S47 belongs to these groups or families:

Tradenames

Main tradenames from several countries containing C6468H10016N1728O2012S47 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 146.000 daltons
VD 0.17 - 0.23 l/Kg
Tmax 168 hours
T½ 331 -360 hours

References

  1. Yeich A, Elhatw A, Ashoor Z, Park K, Craig T. Safety of medications for hereditary angioedema during pregnancy and lactation. Expert Opin Drug Saf. 2023 Jan;22(1):17-24. Consulted on Sept. 22, 2023 Abstract
  2. Stratigakis A, Paty D, Zou P, Zhao Z, Li Y, Zhang T. A regression approach for assessing large molecular drug concentration in breast milk. Reprod Breed 2023;3:199-207 Full text (link to original source) Full text (in our servers)
  3. EMA. Lanadelumab. Ficha técnica. 2018 Full text (in our servers)
  4. Shire Ph. Lanadelumab. Drug Summary. 2018 Full text (in our servers)
  5. Bouillet L, Lehmann A, Gompel A, Boccon-Gibod I, Launay D, Fain O; CREAK.. Traitements des angiœdèmes héréditaires : recommandations du centre de référence national des angiœdèmes (consensus 2014 de Bordeaux). [Hereditary angiœdema treatments: Recommendations from the French national center for angiœdema (Bordeaux consensus 2014)]. Presse Med. 2015 Abstract

Total visits

252

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM